Frontiers in oncology · 2026
Dose-dependent tuning of HSP70-Beclin-1 by kaempferol governs autophagy and chemosensitivity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Suqin, Guo Yanan, Li Mingyan, Jin Fangli, Luo Lei, Yan Zhihuan, Wang Jing, Liu Bao, Zhang Qinsheng, Luo Wenzhao
Аннотация
INTRODUCTION: Autophagy can either support cell survival or promote cell death in response to therapeutic stress, yet the molecular switch that determines this directionality remains poorly defined.
METHODS: Using kaempferol as a proof‑of‑concept flavonoid and esophageal squamous carcinoma cells as a model system, we investigated its dose‑dependent effects on the HSP70-Beclin‑1 complex. In vivo experiments were also performed to evaluate kaempferol's modulation of cisplatin's antitumor activity.
RESULTS: Low‑dose kaempferol stabilized the HSP70-Beclin‑1 association, suppressed autophagic flux, and attenuated chemotherapy‑induced apoptosis. In contrast, high‑dose kaempferol disrupted this complex and enhanced autophagic flux through coordinated activation of AMPK/mTOR inhibition and ER stress-JNK signaling, leading to robust autophagy‑dependent chemosensitization. In vivo, high‑dose kaempferol potentiated cisplatin's antitumor activity, whereas low‑dose kaempferol diminished it.
DISCUSSION: These findings reveal a generalizable molecular logic in which dose‑dependent modulation of a chaperone-autophagy initiation complex governs autophagy directionality and therapeutic response. By elucidating how a single compound can toggle this central regulatory node, the study provides a conceptual framework for optimizing the dosing of natural products and for leveraging autophagy‑based chemosensitization strategies across diverse tumor contexts.
METHODS: Using kaempferol as a proof‑of‑concept flavonoid and esophageal squamous carcinoma cells as a model system, we investigated its dose‑dependent effects on the HSP70-Beclin‑1 complex. In vivo experiments were also performed to evaluate kaempferol's modulation of cisplatin's antitumor activity.
RESULTS: Low‑dose kaempferol stabilized the HSP70-Beclin‑1 association, suppressed autophagic flux, and attenuated chemotherapy‑induced apoptosis. In contrast, high‑dose kaempferol disrupted this complex and enhanced autophagic flux through coordinated activation of AMPK/mTOR inhibition and ER stress-JNK signaling, leading to robust autophagy‑dependent chemosensitization. In vivo, high‑dose kaempferol potentiated cisplatin's antitumor activity, whereas low‑dose kaempferol diminished it.
DISCUSSION: These findings reveal a generalizable molecular logic in which dose‑dependent modulation of a chaperone-autophagy initiation complex governs autophagy directionality and therapeutic response. By elucidating how a single compound can toggle this central regulatory node, the study provides a conceptual framework for optimizing the dosing of natural products and for leveraging autophagy‑based chemosensitization strategies across diverse tumor contexts.